Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 9/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 7/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | LTA4H | P09960 | 2/20 | 0.49 |
| ▸ | XDH | P47989 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.47 |
| ▸ | ATP4A | P20648 | 4/20 | 0.45 |
| ▸ | ATP4B | P51164 | 4/20 | 0.45 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4466554 | 0.88 | RAB9A (0.44) | CYP2D6CYP19A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL4466539 | 0.87 | MAPT (0.45) | KDM4ENPC1ALDH1A1MAPTHPGD | |
| SCHEMBL4686964 | 0.86 | MCL1 (0.46) | NPC1MAPTRAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL4686443 | 0.86 | LTA4H (0.52) | KDM4EALDH1A1LTA4H | |
| SCHEMBL4466562 | 0.86 | RAB9A (0.45) | NPC1ALDH1A1MAPTRAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL4457382 | 0.85 | LTA4H (0.51) | KDM4EALDH1A1LTA4HATP4AATP4B | |
| SCHEMBL4456550 | 0.85 | KDM4E (0.40) | CYP2D6CYP19A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL5750527 | 0.83 | LMNA (0.44) | CYP1A2CYP2C19NPC1ALDH1A1MAPT | |
| SCHEMBL4455245 | 0.83 | NPC1 (0.50) | KDM4ENPC1ALDH1A1MAPTRAB9A | |
| SCHEMBL4457259 | 0.82 | RAB9A (0.45) | KDM4ENPC1ALDH1A1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7534805-B2 | Imidazole derivatives, their preparation and their use as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2009-05-19 | — | — | US | claimed |
| EP-1638943-B1 | NOVEL IMIDAZOLE DERIVATIVES, THE PRODUCTION THEREOF, AND THE USE OF THE SAME AS A MEDICAMENT | SOD CONSEILS RECH APPLIC (FR) | 2008-08-06 | — | — | EP | claimed |
| US-20070066542-A1 | Novel imidazole derivatives, their preparation and their use as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATION SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2007-03-22 | — | — | US | claimed |
| CN-1795179-A | Novel imidazole derivatives, the production thereof, and the use of the same as a medicament | SOD CONSEILS RECH APPLIC (FR) | 2006-06-28 | — | — | CN | claimed |
| US-7534805-B2 | Imidazole derivatives, their preparation and their use as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2009-05-19 | — | — | US | disclosed |
| EP-1638943-B1 | NOVEL IMIDAZOLE DERIVATIVES, THE PRODUCTION THEREOF, AND THE USE OF THE SAME AS A MEDICAMENT | SOD CONSEILS RECH APPLIC (FR) | 2008-08-06 | — | — | EP | disclosed |
| US-20070066542-A1 | Novel imidazole derivatives, their preparation and their use as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATION SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2007-03-22 | — | — | US | disclosed |
| CN-1795179-A | Novel imidazole derivatives, the production thereof, and the use of the same as a medicament | SOD CONSEILS RECH APPLIC (FR) | 2006-06-28 | — | — | CN | disclosed |
| EP-1638943-A2 | NOVEL IMIDAZOLE DERIVATIVES, THE PRODUCTION THEREOF, AND THE USE OF THE SAME AS A MEDICAMENT | Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) (FR) | 2006-03-29 | — | — | EP | disclosed |
| WO-2004106307-A2 | NOVEL IMIDAZOLE DERIVATIVES, THE PRODUCTION THEREOF, AND THE USE OF THE SAME AS A MEDICAMENT | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066542-A1 | Novel imidazole derivatives, their preparation and their use as medicaments | MIF, MCL1, PPIP5K2 | CYP2D6 292/4885CYP19A1 2014/4885CYP1A2 567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.